SCHEMBL2378331

SCHEMBL2378331

O=S(=O)(c1cccc(Br)c1)N1CCN(CCO)CC1

nearest known ligand 0.70

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.70
KMT2A Q03164 1/20 0.70
MBTD1 Q05BQ5 1/20 0.53
L3MBTL3 Q96JM7 1/20 0.53
L3MBTL1 Q9Y468 2/20 0.51
ALDH1A1 P00352 2/20 0.50
GPR183 P32249 1/20 0.49
HTR6 P50406 3/20 0.47
HTR7 P34969 2/20 0.46
HTR1A P08908 1/20 0.46
DRD2 P14416 1/20 0.46
HTR1D P28221 1/20 0.46
HTR1B P28222 1/20 0.46
DRD3 P35462 1/20 0.46
SIRT2 Q8IXJ6 1/20 0.46
GAA P10253 1/20 0.45
MAPT P10636 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2379860 0.83 MEN1 (0.66) MEN1KMT2AMBTD1L3MBTL3ALDH1A1
SCHEMBL2377868 0.82 ALDH1A1 (0.65) ALDH1A1GAAMAPT
SCHEMBL28850441 0.82 MEN1 (0.62) MEN1KMT2AMBTD1L3MBTL3L3MBTL1
SCHEMBL10979638 0.82 POLB (0.62) MEN1KMT2AALDH1A1HTR6GAA
SCHEMBL2379666 0.81 POLB (0.65) MEN1KMT2AMBTD1L3MBTL3HTR6
SCHEMBL263317 0.79 MBTD1 (0.73) MEN1KMT2AMBTD1L3MBTL3ALDH1A1
SCHEMBL3384758 0.79 MBTD1 (0.68) MEN1KMT2AMBTD1L3MBTL3ALDH1A1
SCHEMBL2378503 0.78 HTR2A (0.52) MEN1KMT2AALDH1A1GAA
SCHEMBL2377670 0.78 ALDH1A1 (0.58) MEN1KMT2AL3MBTL1ALDH1A1GAA
SCHEMBL3391959 0.77 MBTD1 (0.71) MEN1KMT2AMBTD1L3MBTL3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2050749-B1 PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF CHUGAI PHARMACEUTICAL CO LTD (JP) 2017-11-22 EP disclosed
US-8846687-B2 Pyrazine compounds as PI3 kinase inhibitors NOVARTIS AG (CH) 2014-09-30 US disclosed
CN-101501035-B Pyrimidine derivatives as PI3K inhibitors and uses thereof CHUGAI PHARMACEUTICAL CO LTD 2013-01-23 CN disclosed
US-20120214800-A1 Organic Compounds NOVARTIS AG (CH) 2012-08-23 US disclosed
US-8022205-B2 Pyrimidine derivatives as PI3K inhibitor and use thereof CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-09-20 US disclosed
CN-102036961-A Pyridine and pyrazine compounds as PI3K inhibitors NOVARTIS AG 2011-04-27 CN disclosed
US-20100069629-A1 PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-03-18 US disclosed
CN-101501035-A Pyrimidine derivatives as P13K inhibitors and uses thereof CHUGAI PHARMACEUTICAL CO LTD (JP) 2009-08-05 CN disclosed
EP-2050749-A1 PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069629-A1 PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF PIK3CA, AKT3, AKT1 MEN1 2881/4885KMT2A 2799/4885MBTD1 1470/4885
US-20120214800-A1 Organic Compounds AR, TRPA1, IL33 MEN1 3526/4885KMT2A 1428/4885MBTD1 3075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.